Centrient Pharmaceuticals on Monday started operation at its new dedicated manufacturing unit at Toansa in Punjab with an objective to scale up production capacity of statins in India.
“With doubling of our production capacity, we demonstrate our commitment to maintain our leadership position in line with our strategy and to continue supporting our customers’ business growth. Guided by our brand promise of Quality, Reliability and Sustainability, Centrient’s Rosuvastatin and Atorvastatin offer superior performance in all three areas to benefit of our customers and the environment,” said Frans Vlaar, the Chief Commercial Officer at Centrient.
Statins are currently the most prescribed drug class globally for the treatment of high cholesterol and cardiovascular diseases and are among the top-selling drugs worldwide.
